The Importance of Beta- Blockers in Patients with Heart Failure: A Resynchronization- Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis. L. Brent Mitchell, Jean L. Rouleau, Gary E. Newton, Jonathon Howlett, Elizabeth Yetisir, George A. Wells, Anthony S.L. Tang
17
Embed
The Importance of Beta-Blockers in Patients with Heart Failure: A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
The Importance of Beta-Blockers in Patients with Heart Failure:
A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT)
Analysis.
L. Brent Mitchell, Jean L. Rouleau, Gary E. Newton, Jonathon Howlett, Elizabeth Yetisir, George A. Wells, Anthony S.L. Tang
DECLARATION - 1
Beta-Blockers
ACE-I / ARB
Aldo Block
CRT
Declaration of Potential Conflict of Interest
• I have nothing to declare
BACKGROUND - 1
Beta-Blockers
ACE-I / ARB
Aldo Block
ICD
CRT
CHF - Proven Effective Therapies on All-Cause Mortality
• multicenter, randomized, two parallel-group, clinical trial
• 1798 patients with NYHA II/III congestive heart failure
• receiving optimal medical therapy
• with LVEF ≤ 0.30 and QRSd ≥ 120ms (≥ 200ms if V-paced)
• and with an independent indication for an ICD
• were randomized 1:1 to receive an ICD or a CRT-ICD
Resynchronization-defibrillation for Ambulatory heart Failure Trial (RAFT)
BACKGROUND - 2
RAFT Results: Death or CHF Hospitalization
BACKGROUND - 3
0
10
20
40
50
30
Cu
mu
lati
ve In
cid
ence
1 2 3 4 60
Years of Follow-up
5
60ICD
CRT-ICD
HR = 0.7595% CI: 0.64 – 0.87p < 0.001
Tang AS et al. N Engl J Med 363:2385-95, 2010
BACKGROUND - 4
CHF - Proven Effective Therapies on All-Cause Mortality
Beta-Blockers
ACE-I / ARB
Aldo Block
ICD
CRT
PURPOSE
To assess the contemporary importance,
independence, and dose-dependence of
beta-blocker therapy in the congestive
heart failure patients studied in RAFT.
METHODS
PATIENT POPULATION: RAFT patients that were treatedwith one of bisoprolol, carvedilol, or metoprolol.
BETA-BLOCKER TARGET DOSAGES: were as defined byESC guidelines1 - bisoprolol 10 mg/d, carvedilol 50 mg/d,metoprolol 200 mg/d.
PRIMARY OUTCOME: death or CHF hospitalization.
STATISTICS: Times to outcome displayed as KM curves.Sixteen variables were included in stepwise proportionalhazards analyses.
1. McMurray JJV et al. Eur Heart J 33:1787-847, 2012
RESULTS - 1
The RAFT Patient Population:
• N = 1798, mean age 66 yrs, 83% male, 67% ischemic• 80% NYHA Class II, mean LVEF 0.23• 90% beta-blocker use, 97% ACE-I / ARB use• 42% spironolactone use
This Substudy Patient Population (82%):
• N = 1474, mean age 66 yrs, 83% male, 66% ischemic• 82% NYHA Class II, mean LVEF 0.23• 100% beta-blocker use, 97% ACE-I / ARB use• 42% spironolactone use
lower estimated GFR (per 5 units) 1.10 (1.01-1.16) 0.0002
0
20
40
1 2 3 4 60 5
60
0
20
40
1 2 3 4 60 5
60
0
20
40
1 2 3 4 60 5
60
RESULTS - 6
Death / CHF Hospitalization by Beta-Blocker Dosage
Years of Follow-up
< 50%
≥ 50%Inc
ide
nc
e
0
20
40
1 2 3 4 60 5
60
Inc
ide
nc
e
by beta-blocker dosage (N=1474)
Years of Follow-up
< 50%
< 50%
< 50%
≥ 50%
≥ 50%
≥ 50%
by carvedilol dosage (N=629)
by bisoprolol dosage (N=489)
by metoprolol dosage (N=356)
p < 0.0001 p < 0.0001
p < 0.0001 p = 0.006
0
20
40
1 2 3 4 60 5
60
0
20
40
1 2 3 4 60 5
60
RESULTS - 7C
um
ula
tive
Inci
den
ce
Years of Follow-up
Death / CHF Hospitalization by RAFT Randomisation
Randomised to CRT-ICD (N=740)
Years of Follow-up
p < 0.001 p = 0.07
Randomised to ICD (N=734)
< 50%
≥ 50%
< 50%
≥ 50%
• independent predictors of death / CHF hospitalization were:
• beta-blockers use at < 50% (not ≥ 50%) of target dosage• use of an ICD (not a CRT-ICD)• ischemic heart disease and previous CABG• peripheral vascular disease or impaired renal function
• with lower dosage these outcome were 50% more likely
• there were no efficacy differences among the beta-blockers•
• carvedilol is more often used at ≥ 50% of target dosages
• the superiority of higher beta-blocker dosages are less evident in CRT-ICD patients than in ICD patients
INFERENCES
In this subgroup analysis of CHF patients studied in RAFT:
The Importance of Beta-Blockers in Patients with Heart Failure:
A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT)
Analysis.
L. Brent Mitchell, Jean L. Rouleau, Gary E. Newton, Jonathon Howlett, Elizabeth Yetisir, George A. Wells, Anthony S.L. Tang